GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 14, 2023, discloses the vesting of Performance Share Plan (PSP) awards granted in February 2020 to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The awards covered a three-year performance period from January 1, 2020, to December 31, 2022. The filing details the vesting outcomes based on specific business performance metrics and the subsequent sale of shares to meet tax liabilities.
Key Financial Metrics and Performance Outcomes
The filing provides specific performance data used to calculate vesting levels for the 2020 PSP awards. The overall vesting level for the 2020 award was 52%, with 48% of the award lapsed.
| Performance Measure | Weight | Outcome | Vesting % |
|---|---|---|---|
| Adjusted Free Cash Flow | 30% | £13.08bn achieved (Target: £10.47bn) | 100% |
| Total Shareholder Return | 30% | Ranked 9th (Below threshold) | 0% |
| Innovation Sales | 20% | £15.368bn achieved (Target for 50%: £15.660bn) | 41% |
| Pipeline Progress | 20% | 88% achievement (Pivotal trials and approvals) | 50% |
Share Prices on Vesting Date (Feb 10, 2023):
- Ordinary Shares: £14.73
- American Depositary Shares (ADSs): $35.84
Material Changes and Transactions
The filing reports the vesting of shares and ADSs for multiple executives, including the CEO, CFO, and other senior officers. Following vesting, several executives sold portions of their shares to cover tax liabilities.
- Ms E Walmsley (CEO): 237,385 Ordinary Shares vested.
- Mr I Mackay (CFO): 125,432 Ordinary Shares vested.
- Ms D Conrad (Chief People Officer): 48,698 Ordinary Shares vested; 26,069 shares sold at £14.7818 to meet tax liabilities.
- Mr J Ford (SVP, Legal): 78,211 Ordinary Shares vested; 36,760 shares sold at £14.7818 to meet tax liabilities.
- Ms S Ramakrishnan (CTO): 4,065 ADSs vested; 2,169 ADSs sold at $35.7274 to meet tax liabilities.
The filing does not provide comparative financial data for the prior period as it is a transaction notification rather than a financial results report.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the disclosure of the performance metrics used for vesting. It notes that vested shares for Executive Directors are subject to an additional two-year vesting period.
Key Facts for Investor Verification
- Performance Success: The company significantly exceeded its Adjusted Free Cash Flow target, achieving 100% vesting on that metric.
- Shareholder Return Lag: The company failed to meet the Total Shareholder Return threshold, resulting in 0% vesting for that portion of the award.
- Innovation Sales: Innovation sales fell slightly short of the target required for 50% vesting, resulting in a 41% payout for that metric.
- Executive Retention: Vested shares for Executive Directors are subject to a two-year holding period, indicating a strategy to align long-term interests.
- Tax Sales: Multiple executives sold shares immediately upon vesting to cover tax obligations, which is a standard procedure but confirms the liquidity of the awards.